| Identification | Back Directory | [Name]
1-(4-((3'-Chloro-6-Methoxy-[1,1'-biphenyl]-3-yl)Methyl)phenyl)urea | [CAS]
1155877-97-6 | [Synonyms]
D159687
D159687; D-159687; D 159687
1-(4-((3'-chloro-6-methoxybiphenyl-3-yl)methyl)phenyl)urea
1-(4-((3'-Chloro-6-Methoxy-[1,1'-biphenyl]-3-yl)Methyl)phenyl)urea
Urea, N-[4-[(3'-chloro-6-methoxy[1,1'-biphenyl]-3-yl)methyl]phenyl]- | [Molecular Formula]
C21H19ClN2O2 | [MDL Number]
MFCD26793458 | [MOL File]
1155877-97-6.mol | [Molecular Weight]
366.84 |
| Chemical Properties | Back Directory | [Boiling point ]
502.0±50.0 °C(Predicted) | [density ]
1.263±0.06 g/cm3(Predicted) | [storage temp. ]
Sealed in dry,Room Temperature | [solubility ]
DMSO : 150 mg/mL (408.90 mM) | [form ]
Solid | [pka]
14.48±0.50(Predicted) | [color ]
White to off-white | [InChI]
1S/C21H19ClN2O2/c1-26-20-10-7-15(12-19(20)16-3-2-4-17(22)13-16)11-14-5-8-18(9-6-14)24-21(23)25/h2-10,12-13H,11H2,1H3,(H3,23,24,25) | [InChIKey]
RJJLUTWHJUDZFP-UHFFFAOYSA-N | [SMILES]
Clc1cc(ccc1)c2c(ccc(c2)Cc3ccc(cc3)NC(=O)N)OC |
| Hazard Information | Back Directory | [Uses]
D-159687 is a selective inhibitor of cyclic AMP phosphodiesterase 4D (PDE4D). | [Biological Activity]
D159687 is a brain-penetrantorally availablehighly potent and selective negative allosteric modulator (NAM) against phosphodiesterase 4 (PDE4) subtype PDE4D (hPDE4D7 IC50 = 27 nM; PDE4A1/B1/C1 IC50 = 2.50/1.47/6.80 μM; IC50 ≥29 μM against PDE1/2/3/5/7/8/9/10/11 subtypes). Comparing to RolipramD159678 offers similar in vivo efficacy on long-term memory formation by novel object recognition test (MED = 3 μg/kg mouse iv.1 μg/kg r at p.o.)while being more effective in the scopolamine-impaired Y-maze tests (D159678/Rolipram MED = 0.1/1 μg/kg mouse iv. or 30/100 μg/kg mouse p.o.) and much less emetic in shrews/dog/monkeys (by 100-/3000-/500-fold). | [in vivo]
D159687 (0.05-5 mg/kg; oral daily for a week) shows a potential recruitment or enhancement of synaptic function with increased task difficulty in female Cynomolgus macaques[2]. | Animal Model: | Female Cynomolgus macaques (4–6 year old) [2] | | Dosage: | 0.05, 0.5, 5 mg/kg | | Administration: | Oral daily for a week | | Result: | A potential recruitment or enhancement of synaptic function with increased task difficulty. |
| [IC 50]
PDE4 |
|
| Company Name: |
SPIRO PHARMA
|
| Telephone: |
|
| Website: |
www.spiropharma.com.cn |
|